IOVA Jun 2024 13.500 call
| Previous close | 0.6500 |
| Open | 0.6500 |
| Bid | 0.0000 |
| Ask | 1.0000 |
| Strike | 13.50 |
| Expiry date | 2024-06-28 |
| Day's range | 0.6500 - 0.6500 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
GlobeNewswireIovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma
First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000 Patients Annually with Previously Treated Advanced Melanoma SAN CARLOS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, submitted a marketing authorization
- GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., June 21, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on June 20, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 187,650 shares of Iovance’s common stock to forty-three new,
Simply Wall St.Exploring Three US Growth Companies With Substantial Insider Ownership
Amidst a backdrop of fluctuating markets and evolving economic indicators, the U.S. stock market has shown resilience in various sectors despite recent downturns in tech giants. As investors navigate through these uncertain times, understanding the role of insider ownership in growth companies becomes increasingly relevant. In this environment, companies with substantial insider ownership can be appealing as they often indicate a leadership team deeply invested in the company's long-term...
